(0.29%) 5 114.64 points
(0.38%) 38 385 points
(0.33%) 15 980 points
(-1.36%) $82.71
(6.29%) $2.04
(-0.05%) $2 346.10
(-0.27%) $27.46
(3.89%) $958.00
(-0.21%) $0.933
(-0.32%) $10.99
(-0.54%) $0.796
(1.65%) $93.39
Quarter results today
(bmo 2024-04-29)
Expected move: +/- 4.34%
-0.66% INR 142.70
Live Chart Being Loaded With Signals
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India...
Stats | |
---|---|
Dagens volum | 78 384.00 |
Gjennomsnittsvolum | 199 373 |
Markedsverdi | 8.74B |
EPS | INR0 ( 2024-04-05 ) |
Last Dividend | INR0.750 ( 2011-09-19 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -71.35 |
ATR14 | INR0.162 (0.11%) |
Volum Korrelasjon
Panacea Biotec Limited Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Panacea Biotec Limited Korrelasjon - Valuta/Råvare
Panacea Biotec Limited Økonomi
Annual | 2022 |
Omsetning: | INR4.60B |
Bruttogevinst: | INR2.07B (45.07 %) |
EPS: | INR-5.51 |
FY | 2022 |
Omsetning: | INR4.60B |
Bruttogevinst: | INR2.07B (45.07 %) |
EPS: | INR-5.51 |
FY | 2022 |
Omsetning: | INR6.59B |
Bruttogevinst: | INR3.59B (54.49 %) |
EPS: | INR175.98 |
FY | 2021 |
Omsetning: | INR6.18B |
Bruttogevinst: | INR3.89B (63.00 %) |
EPS: | INR-24.11 |
Financial Reports:
No articles found.
Panacea Biotec Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR1.000 | 2002-08-13 |
Last Dividend | INR0.750 | 2011-09-19 |
Next Dividend | INR0 | N/A |
Payout Date | 2011-10-10 | |
Next Payout Date | N/A | |
# dividends | 9 | -- |
Total Paid Out | INR8.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.72 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0.986 | |
Div. Directional Score | 0.442 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TATAINVEST.NS | Dividend Junior | 2023-06-12 | Annually | 27 | 1.85% | |
NLCINDIA.NS | Dividend Knight | 2023-09-18 | Annually | 25 | 3.45% | |
INDIGOPNTS.NS | Dividend Junior | 2023-07-28 | Annually | 3 | 0.11% | |
CLSEL.NS | Dividend Junior | 2023-09-21 | Sporadic | 4 | 0.27% | |
SARDAEN.NS | Dividend Junior | 2023-09-07 | Annually | 15 | 0.65% | |
MAGADSUGAR.NS | Dividend Junior | 2023-07-13 | Annually | 7 | 1.78% | |
GMDCLTD.NS | Dividend Knight | 2023-09-22 | Annually | 23 | 3.41% | |
ASTRAMICRO.NS | Dividend Junior | 2023-08-23 | Annually | 20 | 0.49% | |
TITAN.NS | Dividend Junior | 2023-07-13 | Annually | 20 | 0.35% | |
PETRONET.NS | Dividend Knight | 2023-08-18 | Semi-Annually | 18 | 2.36% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0222 | 1.500 | -0.445 | -0.667 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.0145 | 1.500 | -1.273 | -1.909 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 2.63 | 1.000 | -0.137 | -0.137 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.22 | 2.00 | 5.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.22 | 2.00 | 3.89 | 7.78 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.484 | 1.000 | 5.27 | 5.27 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.107 | 1.000 | -4.14 | -4.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.101 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -72.13 | 1.000 | -7.39 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0145 | 2.50 | -0.818 | -1.909 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.22 | 2.00 | 5.93 | 7.78 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.22 | 2.00 | 5.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.482 | 1.500 | -6.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.136 | 1.000 | 9.11 | 0 | [0.1 - 0.5] |
Total Score | 0.986 |
Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.